biote (NASDAQ:BTMD – Get Free Report) and Tempus AI (NASDAQ:TEM – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
Institutional & Insider Ownership
21.7% of biote shares are owned by institutional investors. Comparatively, 24.2% of Tempus AI shares are owned by institutional investors. 32.4% of biote shares are owned by company insiders. Comparatively, 24.3% of Tempus AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for biote and Tempus AI, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| biote | 1 | 1 | 1 | 1 | 2.50 |
| Tempus AI | 1 | 10 | 11 | 0 | 2.45 |
biote presently has a consensus target price of $2.50, indicating a potential upside of 131.48%. Tempus AI has a consensus target price of $79.37, indicating a potential downside of 1.45%. Given biote’s stronger consensus rating and higher possible upside, equities analysts plainly believe biote is more favorable than Tempus AI.
Profitability
This table compares biote and Tempus AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| biote | -1.08% | -8.84% | 4.64% |
| Tempus AI | -12.54% | -47.00% | -9.44% |
Risk & Volatility
biote has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Tempus AI has a beta of 3.61, suggesting that its share price is 261% more volatile than the S&P 500.
Valuation & Earnings
This table compares biote and Tempus AI”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| biote | $192.22 million | 0.20 | $27.05 million | ($0.10) | -10.80 |
| Tempus AI | $1.27 billion | 11.55 | -$245.03 million | ($1.06) | -75.98 |
biote has higher earnings, but lower revenue than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Summary
biote beats Tempus AI on 10 of the 15 factors compared between the two stocks.
About biote
Biote Inc. (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services. The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.
About Tempus AI
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
